Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 6/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276495 | 0.88 | EGFR (0.46) | EGFRERBB2KDRMAPK14FGFR1 | |
| Hydrochloric Acid SCHEMBL275478 | 0.87 | EGFR (0.45) | EGFRERBB2KDRMAPK14FGFR1 | |
| SCHEMBL744286 | 0.87 | EGFR (0.42) | EGFRERBB2KDRMAPK14TEAD2 | |
| SCHEMBL276526 | 0.85 | MAP2K1 (0.46) | EGFRERBB2JAK2JAK3KDR | |
| SCHEMBL761901 | 0.84 | FGFR1 (0.36) | EGFRERBB2KDRFGFR1ALDH1A1 | |
| SCHEMBL275481 | 0.82 | MAPT (0.54) | EGFRERBB2RAB9ASMN1; SMN2 | |
| SCHEMBL3611837 | 0.82 | EGFR (0.49) | EGFRERBB2JAK3KDRFGFR1 | |
| SCHEMBL15221845 | 0.81 | EGFR (0.46) | EGFRERBB2JAK3KDRMAPK14 | |
| SCHEMBL741772 | 0.80 | EGFR (0.41) | EGFRERBB2KDRMAP2K1KDM4E | |
| SCHEMBL3621896 | 0.80 | EGFR (0.59) | EGFRERBB2JAK3KDRFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138336-B2 | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | BAYER HEALTHCARE LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100273800-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273800-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | AURKC, AURKA, PLK1 | EGFR 1566/4885ERBB2 838/4885JAK2 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.